Notes on Peripheral Nervous System Disorders (Video Transcript)

Peripheral Nervous System: Key Concepts and Conditions

• The main neurotransmitter in the peripheral nervous system (PNS) is acetylcholine.
• Disorders can arise from disruption of peripheral nerves and muscles (outside the brain and spinal cord) and can include progressive weakness, sensory changes, and autonomic symptoms. The nursing process emphasizes airway/Breathing first, then mobility/strength, cognition, and functional outcomes.
• Many PNS disorders have autoimmune or infection-related components and can be chronic or progressive with potential remissions and relapses.
• Diagnostic approaches commonly mentioned in the transcript include history/physical, imaging (MRI, CT), nerve conduction studies/EMG, lumbar puncture with CSF analysis, antibody testing, and viral serology. Treatments frequently involve immunomodulation, symptom control, and supportive care.

Multiple Sclerosis (MS)

• Pathophysiology (as described): autoimmune degeneration of the myelin sheath surrounding neurons, leading to exposed nerves, slowed or blocked impulses, and inflammation with plaque buildup.
  • Myelin sheath damage causes sensory/motor deficits because nerve impulses slow or fail.
  • Often described as autoimmune in origin; potential viral triggers discussed (Epstein–Barr virus, HIV, HPV) with antibody testing mentioned.
• Demographics and risk factors (from transcript): usually affects women; heredity is a risk factor; age is a risk factor; population described as light-skinned; disease typically presents in younger adults.
• Symptomatology (major and recurring themes):
  • Fatigue (very common in young women with MS)
  • Muscle weakness, numbness
  • Visual disturbances (cloudy vision, peripheral vision changes)
  • Dizziness, ataxia; gait impairment progressing over years
  • Dysphagia; bowel and bladder problems (neurogenic bladder)
  • Mood alterations (anger, depression)
  • Mobility limitations; increasing need for assistive devices over time (cane → crutches → walker → wheelchair)
• Disease course and types (as described): remitting-relapsing and relapsing-remitting patterns; progression over time is common; emphasis on recurring symptoms and varied relapse patterns
• Diagnostic approaches (notable tests mentioned):
  • Lumbar puncture with CSF analysis showing immunoglobulin (IgG) elevations/antibody activity
  • MRI to detect plaques and inflamed nerves
  • Nerve conduction studies/EMG to assess conduction and function
  • Viral serologies and antibody testing to explore autoimmune triggers
• Therapeutic approaches (key points emphasized):
  • Acute management with steroids to reduce inflammation
  • Immunomodulatory therapies such as interferon and other immunosuppressants
  • Symptom management: baclofen for spasticity, physical/occupational/speech therapy
  • Management of neurogenic bladder and stool/urinary issues; infection prevention; vaccinations
  • Energy conservation and rest strategies due to fatigue
• Practical/real-world implications: stress and infections can trigger exacerbations; extremes of temperature may worsen symptoms; the disease often requires long-term planning for mobility and daily function
• Connections and significance: MS is highlighted as an autoimmune CNS demyelinating disorder with relapsing/remitting courses; emphasizes monitoring for vision changes, gait, bladder function, and hydration/nutrition; highlights the importance of multidisciplinary care and infection prevention

Myasthenia Gravis (MG)

• Pathophysiology: autoimmune involvement with antibodies against acetylcholine receptor (AChR) at the neuromuscular junction, leading to impaired neuromuscular transmission and muscle weakness that worsens with use and improves with rest.
• Key distinguishing features: bulbar/ocular involvement (ptosis, diplopia, dysphagia, dysarthria) with fluctuating weakness; respiratory muscles can be affected, risking respiratory failure.
• Treatments/therapies (major points):
  • Acetylcholinesterase inhibitors (e.g., pyridostigmine, mesinon [mes-], prostigmine) to improve neuromuscular transmission; dosing often tied to meals (e.g., take ~45 minutes before meals) and should not be abruptly stopped
  • Immunosuppressive therapy and steroids to reduce autoimmune activity
  • Thymus-related considerations: thymectomy discussed as a potential intervention due to thymic involvement in MG
  • Short-term rescue therapies: Tensilon test (edrophonium) to assess improvement in muscle strength (positive Tensilon test)
  • Imaging/labs for diagnosis: antibodies to AChR, EMG/nerve conduction studies, chest CT to evaluate thymus
• Crisis states and management: two key crises
  • Myasthenic crisis: improvement with medication loss; risk of respiratory failure if missed doses; ABGs and pulmonary function tests (PFTs) important for respiratory assessment; emphasize strict adherence to dosing schedules
  • Cholinergic crisis: due to excessive acetylcholinesterase inhibition; signs summarized by SLUDGE: Salivation, Lacrimation, Urination, Diarrhea, Emesis; atropine as antidote
• Practical nursing considerations/education:
  • Ensure adherence to medication timing; if a dose is missed, take as soon as remembered, then resume regular schedule (do not double-dose strictly, but if within the window you may adjust; follow clinical guidance)
  • Monitor airway, breathing, and swallowing; assess risk for aspiration; monitor for signs of respiratory compromise
  • Watch for infections which can precipitate crises; infection prevention is crucial
  • Discuss nutrition and swallowing safety; watch for bulbar muscle involvement
• Notable notes: Tensilon test and antibody testing are central to diagnosis; thymectomy may be considered; MG is autoimmune-related with sensitivity to respiratory infections; steroids and immunosuppressants used to control disease activity

Amyotrophic Lateral Sclerosis (ALS)

• Pathophysiology: degeneration of motor neurons leading to progressive weakness and loss of muscle coordination; eventual paralysis of nearly all voluntary muscles; senses and intellect typically preserved early on
• Prognosis: rapid progression with significant disability; historically about $5 ext{ years}$ from diagnosis to death, though individual variation exists
• Clinical features: fast-progressing weakness and atrophy, impaired coordination, and eventual respiratory failure; difficulty chewing and swallowing as the disease advances; risk of aspiration and pneumonia; speech may be affected; cognition usually preserved
• Management and care approaches (as described):
  • Supportive care: physical, occupational, and speech therapy; nutrition management (weight maintenance and potential tube feeding)
  • Respiratory support: ventilatory support as needed; suction and airway clearance strategies
  • Symptom management: baclofen or similar agents for spasticity; analgesia for neuropathic pain; augmented communication strategies (e.g., eye-tracking devices) when speech is not possible
  • Drug referenced: Refuelo (likely riluzole; discussed as a potential disease-modifying agent in some contexts) – not explicitly named in standard practice in the transcript, but noted as a treatment in the session
• Nursing and caregiver considerations: high-care burden; infection prevention; support for families; coordination with rehab services; ongoing assessment of nutrition and hydration; communication strategies when speech is impaired
• Important context: the disease is rapidly progressive; the senses are typically intact; this underscores the need for comprehensive supportive care and assistive technologies for quality of life

Guillain-Barré Syndrome (GBS)

• Pathophysiology: inflammatory demyelinating polyneuropathy affecting spinal and cranial nerves; segmental demyelination with immune-mediated attack on nerves; can be motor and sensory
• Course pattern: classically demonstrates ascending weakness that progresses over days to weeks, then plateaus, and subsequently may descend in recovery; onset can be rapid (acute) with weakness appearing within a short timeframe
  • Emphasis in transcript: ascending paralysis that may reach peak strength around two to three weeks, followed by recovery (descending phase) with plateau in between
• Triggers and associations: often precipitated by an infection; viral infections noted (including Zika virus); diabetes mentioned as a potential comorbidity in some contexts
• Respiratory and autonomic risks: airway management is critical; risk of respiratory failure requiring ventilation; autonomic dysfunction may occur (blood pressure fluctuations, cardiac issues)
• Diagnostics and monitoring: ABGs and pulmonary function tests (PFTs) are central to monitoring respiratory status; frequent ABGs; nerve conduction studies/EMG to assess demyelination; high clinical suspicion with rapid progression
• Treatments: plasmapheresis (plasma exchange) or intravenous immunoglobulin (IVIG) as disease-modifying therapies; oxygenation and ventilatory support as needed; rest and gradual rehabilitation and recovery; emotional support and rehab for nervous system function
• Prognosis and recovery: many patients recover with appropriate support; course can vary; comprehensive rehab is essential to regain function
• Nursing considerations: prevent aspiration and infection; monitor respiratory status closely; prepare for potential long-term ventilation and airway clearance strategies; initiate rehab early

Trigeminal Neuralgia (TGN)

• Pathophysiology: compression or irritation of the trigeminal (cranial nerve V) sensory root, causing intense facial pain; pain can be triggered by light touch, vibration, or even a breeze
• Nerve branches involved: ophthalmic (V1), maxillary (V2), and mandibular (V3) branches; pain is typically unilateral and focal to the face
• Symptoms and exam nuances: pain is triggered by stimulation of the face; facial sensation changes; chewing/jaw movement can provoke pain; sensory findings often normal between episodes
• Diagnostic approach: imaging to assess nerve compression (MRI); exam focuses on triggering and pattern rather than widespread deficit
• Treatments/therapies: anticonvulsants (e.g., phenytoin/Dilantin) used for neuropathic pain; nerve blocks with alcohol or anesthetic; surgical options include rhizotomy (microvascular decompression) to cut or relieve nerve signaling
  • Rhizotomy: surgical cutting of nerve fibers to block pain signals; spelled “rhizotomy” (R-h-i-z-o-t-o-m-y)
• Dietary and daily living adaptations: soft foods, room temperature, and easily swallowed foods to reduce chewing/swallowing difficulty; avoid hot/cold foods; use straws to minimize jaw movement during meals; avoid hard or fibrous foods (e.g., celery) that require extensive chewing
• Post-procedure considerations: risk of residual numbness; some patients may require long-term pain management; some may seek cosmetic or surgical remedies if pain recurs
• Pain management and prognosis: anticonvulsants help reduce nerve excitability; many patients experience relief with nerve blocks or surgical intervention; prognosis varies, but many patients achieve substantial pain relief with treatment

Bell’s Palsy (Facial Nerve Palsy, CN VII)

• Pathophysiology: inflammation/edema of the facial nerve causing unilateral facial weakness that can mimic a stroke; motor rather than sensory emphasis
• Key distinguishing features: facial droop, inability to close the eye on the affected side, drooping of the mouth, impaired eye protection due to incomplete blinking
• Eye protection and lubrication: due to inability to blink or close the eye, risk of corneal exposure; use artificial tears, lubricating ointment, and patch the eye if needed; assess and manage tear production and eye humidity
• Taste and speech: taste on the affected side may be impaired; speech may be slurred or difficult to understand in some cases
• Diagnosis: primary concern is differentiating from a stroke; look for the pattern of facial weakness and the presence or absence of accompanying neurological signs; pain behind the ear may be noted in some cases
• Management and prognosis: prednisone (steroids) often used; analgesics for pain; moist heat and gentle massage; facial sling or sling support for drooping muscles; some patients pursue acupuncture or B vitamins; Botox may be used in some cases; many patients improve over time, with some achieving full recovery
• Practical considerations: ensure eye protection and lubrication until normal blinking returns; assess for residual deficits and consider plastic surgery or cosmetic measures if needed
• Notes on exam and differential: emphasize assessing for stroke-like features to rule out cerebrovascular event; Bell’s palsy typically lacks sudden, widespread neurological signs and often improves over weeks to months

General Nursing Diagnoses and Interventions (PNS focus)

• Common nursing diagnoses across PNS disorders include:
  • Impaired airway clearance related to muscle weakness or bulbar dysfunction (MG, MS, GBS, ALS)
  • Acute or chronic pain related to neuropathic or sharp facial pain (trigeminal neuralgia, Bell’s palsy)
  • Activity intolerance and reduced mobility due to weakness or fatigue (MS, MG, ALS, GBS, Nerve disorders)
  • Risk for infection related to immobility, urinary stasis (neurogenic bladder in MS), or respiratory compromise
  • Self-care deficit and communication impairment (ALS, MG, stroke-derived mimics)
  • Disturbed sensory perception or risk for injury due to numbness or paresthesias (trigeminal neuralgia, Bell’s palsy)
• Prioritization and planning: airway and breathing take priority in most neuromuscular disorders due to the high risk of respiratory failure; plan care around modulation of respiratory status, mobility support, nutrition, and infection prevention; reassess outcomes after interventions to determine effectiveness
• Interventions to consider (based on transcript topics):
  • Respiratory support: monitor ABGs and PFTs, perform pulmonary hygiene, prepare for potential ventilation in events of respiratory failure (MS, MG crises, GBS, ALS)
  • Infection prevention: hand hygiene, vaccination, avoidance of crowds during infectious outbreaks; monitor for infections that could trigger disease exacerbations (notably MS and MG)
  • Rest and energy conservation: schedule rest periods; pace activities to manage fatigue (MS, MG, MS-related fatigue)
  • Mobility and safety: assistive devices as needed; fall risk reduction; safe feeding strategies for dysphagia (MG) or dysphagia risk (ALS)
  • Medication education and safety: ensure adherence to acetylcholinesterase inhibitors (MG), autoimmune therapies (MS), spasmolytics (baclofen) for spasticity (MS, ALS, MG), and pain management strategies (trigeminal neuralgia, Bell’s palsy)
  • Nutritional support: monitor weight, caloric intake, and potential tube feeding in advanced disease (ALS, MG with bulbar weakness)
  • Communication strategies: PT/OT/SLP involvement; augmentative communication methods (eye-tracking device described in ALS case)
• Ethical, practical, and real-world implications:
  • Many of these conditions are chronic and progressive; goals of care include maintaining quality of life, maximizing independence where possible, and supporting caregivers
  • Education on disease triggers (stress, infection, heat) and preventive strategies is a key nursing role
  • Early identification of crises (myasthenic vs cholinergic) is critical for timely intervention

Quick Reference: Diagnostic and Therapeutic Keywords to Memorize

• MS: autoimmune CNS demyelination; plaques; fatigue; vision issues; steroids; interferon; immunosuppressants; baclofen; MRI/CSF IgG; relapsing-remitting pattern
• MG: AChR antibodies; ptosis/diplopia; dysphagia; pyridostigmine/mesinon; Tensilon test; thymectomy; crisis management; ABGs/PFTs; avoid infection
• ALS: motor neuron degeneration; rapid progression; respiratory failure; bulbar weakness; nutritional support; baclofen; riluzole (referenced as Refuelo); eye-tracking communication
• GBS: ascending paralysis; autonomic risk; ABGs/PFTs; plasmapheresis/IVIG; respiratory support; recovery can occur with rehabilitation
• Trigeminal neuralgia: facial pain with triggers; anticonvulsants (e.g., phenytoin/Dilantin); imaging for compression; rhizotomy; nerve blocks; soft foods; avoid excessive chewing
• Bell’s palsy: CN VII palsy; facial droop; eye protection; steroids; lubrication; safety and rehabilitation options; differentiate from stroke

Connections to Foundational Principles

• Autoimmune mechanisms repeatedly underlie MS, MG, and GBS, illustrating how immune dysregulation can target different parts of the nervous system (CNS vs PNS).
• Demyelination (MS, GBS) disrupts impulse conduction, leading to weakness, sensory changes, and neuropathic pain; assessment of conduction and myelin integrity (EMG, nerve conduction, MRI) is central to diagnosis.
• The neuromuscular junction (MG) disruption demonstrates how transmission at synapses can be affected by antibodies, with downstream effects on muscle strength and function.
• Respiratory failure is a recurring and critical risk across several conditions (MS with bulbar weakness, MG crisis, GBS, ALS). Early respiratory assessment and intervention are essential.
• Symptom management often emphasizes multidisciplinary care (PT/OT/SLP, nutrition, respiratory therapy) and patient education for disease management and crisis prevention.

Summary Points for Exam Preparation

• Be able to distinguish between CNS (MS) and PNS (MG, GBS, ALS, trigeminal neuralgia, Bell’s palsy) disorders and identify the primary affected structures.
• Recognize hallmark features and triggers: fatigue and optic symptoms in MS; fluctuating limb weakness and bulbar signs in MG; rapid, progressive motor decline with preserved sensation in ALS; ascending paralysis and autonomic involvement in GBS; paroxysmal facial pain in trigeminal neuralgia; unilateral facial droop with eye protection needs in Bell’s palsy.
• Recall key diagnostic tools associated with each condition (CSF IgG, MRI plaques for MS; Tensilon test, AChR antibodies for MG; EMG and nerve conduction; ABGs/PFTs; plasmapheresis in GBS; imaging for trigeminal neuralgia; clinical differentiation from stroke in Bell’s palsy).
• Memorize major treatments and crisis management principles: steroids and interferons for MS; acetylcholinesterase inhibitors and thymectomy for MG; riluzole and supportive care for ALS; plasmapheresis/IVIG and respiratory support for GBS; anticonvulsants and potential surgical options for trigeminal neuralgia; steroids and eye protection for Bell’s palsy.
• Understand crisis definitions and management strategies (myasthenic vs cholinergic crisis; airway management in GBS/ALS; infection prevention across autoimmune conditions).